Fast Growing Mid-Tier Pharmaceutical Company Signs Agreements with eResearchTechnology for Cardiac Safety Monitoring and Informa
November 17 2003 - 8:45AM
PR Newswire (US)
Fast Growing Mid-Tier Pharmaceutical Company Signs Agreements with
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Awards Total Approximately $1.7 million for
Two Studies and Includes Digital Collection, Interpretation, and
Distribution of Cardiac Safety Data PHILADELPHIA, Nov. 17
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a
leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received agreements for approximately $1.7 million in cardiac
safety monitoring and services from a fast growing mid-tier
pharmaceutical for one of its drug candidates in late phase
development. The agreements cover two Phase III studies for a
single compound. Combined, the awards include 80 sites across the
U.S. eRT will provide comprehensive site support and 80 units of
12-lead ECG recording equipment, which is designed to facilitate
the collection of cardiac safety data that are subsequently
provided to eRT for analysis. eRT will manage collection,
measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT workflow enabled data handling
technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and
technical standards. In addition, the agreements include a
subscription to eRT's Digital ECG Community, which delivers timely
cardiac safety data feedback at the trial, center, dosing group,
and patient level, along with related metrics, such as trial
enrollment, as well as the ability to organize and publish a
variety of study-specific information and the ability to link data
points in reports direct to digital ECG waveforms. "We are pleased
to have been awarded these studies, which provide an excellent
example of the breadth of cardiac safety assessment that is
becoming typical of compounds in later phase development, across
the full range of therapeutic areas," said Scott Grisanti, senior
vice president of business development and chief marketing officer
at eRT. "eRT is unique in not only its ability to deliver the
scientific expertise required to achieve excellence in this
important area, but also to provide the extensive logistics and
project assurance services that are critical and especially
important to smaller, fast growing organizations." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-760-487-1137, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles